Lilly bolts another one on, acquiring Point Biopharma for $1.4 billion; Congress extends some pandemic preparedness programs, but not all

Taking stock of the drug industry, from the lab to the medicine chest

October 3, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Darron Cummings/AP STAT+ | Lilly bolts another one on, acquiring Point Biopharma for $1.4 billion Point Biopharma is developing cancer drugs that deliver a focused dose of radiation to tumor cells. By Matthew Herper STAT+ | Congress extends some pandemic preparedness programs, but not all Congress temporarily extended a few pandemic-preparedness programs when it forestalled a government shutdown at the last minute Saturday. By John Wilkerson Opinion: How headlines about the RSV antibody injection could cloud parents' decision-making Beyfortus, the new RSV monoclonal antibody injection for children, is not a vaccine. But you might not know that from journalistic coverage. By David Scales and Sara Gorman and Kathleen Hall Jamieson NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images FDA authorizes Novavax's updated Covid-19 vaccine Like the Moderna and Pfizer vaccines, the Novavax jab is a monovalent, protecting against a single strain of SARS-2. By Helen Branswell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser